뒤로
Shanghai Henlius Biotech Inc(SGBCF) 가격
SGBCF 주가 차트
SGBCF 수입
Shanghai Henlius Biotech Inc
$0
0%
$0
종가: Feb 10, 16:00:00 GMT-5
$0
0%
$0
애프터마켓: Feb 10, 16:51:03 GMT-5
Earnings FAQ
SGBCF의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
Shanghai Henlius Biotech Inc SGBCF의 지난 분기 매출 실적은 어땠나요?
Shanghai Henlius Biotech Inc의 매출 추정치는 얼마인가요?
Shanghai Henlius Biotech Inc의 수익 품질 점수는 얼마인가요?
Shanghai Henlius Biotech Inc는 언제 수익을 보고하나요?
Shanghai Henlius Biotech Inc의 예상 수익은 얼마인가요?
Shanghai Henlius Biotech Inc은 수익 기대치를 충족했나요?
주요 통계
이전 종가
--
시가
--
일일 범위
-
52주 범위
-
거래량
--
평균 거래량
--
EPS(TTM)
--
배당수익률
--
시가총액
--
SGBCF란 무엇인가요?
Shanghai Henlius Biotech, Inc. engages in the production and sale of monoclonal antibody (mAb) drugs and the provision of related consultation and technical services, and the transfer of its own technology. The company is headquartered in Shanghai, Shanghai and currently employs 3,537 full-time employees. The company went IPO on 2019-09-25. The Company’s main products include HANQUYOU (trastuzumab for injection), HANNAIJIA (neratinib maleate), HANSIZHUANG (serplulimab injection), HANLIKANG (rituximab injection), HANDAYUAN (adalimumab injection), HANBEITAI (bevacizumab injection) and others. The Company’s products are mainly used in the treatment of adjuvant breast cancer, metastatic breast cancer, metastatic gastric cancer, metastatic non-squamous non-small cell lung cancer, polyarticular juvenile idiopathic arthritis and others. The firm mainly operates its businesses in the domestic and overseas markets.